Literature DB >> 70478

The role of T cells in anti-herpes simplex virus immunity. I. Induction of antigen-specific cytotoxic T lymphocytes.

K Pfizenmaier, H Jung, A Starzinski-Powitz, M Röllinghoff, H Wagner.   

Abstract

Mice infected with herpes simplex virus develop little or no cytotoxic T lymphocyte (CTL) response. However, in lymph nodes (LN's) draining a local site infected with HSV, antigen-specific CTL precursors are sensitized, which upon transfer to in vitro culture conditions develop within 72 hr into effective CTL. The in vivo blockade of CTL differentiation can be overcome by cyclophosphamide, suggesting that a cyclophosphamide-sensitive mechanism blocks the in vivo generation of HSV-immune CTL. The cytolytic activity of HSV-immune CTL is H-2 restricted and antigen specific. Thus CTL sensitized toward HSV type 1 discriminate between syngeneic targets infected with either the immunologic HSV variant type 1 or type 2 (and vice versa). H-2-matched target cells exposed for 30 min to infectious HSV are lysed within 60 min of contact with CTL. Since HSV replication is believed to require more than 4 to 5 hr, the data suggest that either the expression of HSV-dependent "early proteins" takes place within 30 to 90 min or cell membrane-integrated HSV virion represents the target antigen of CTL.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 70478

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

Review 1.  Heterologous immunity between viruses.

Authors:  Raymond M Welsh; Jenny W Che; Michael A Brehm; Liisa K Selin
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  Endogenous neosynthesis vs. cross-presentation of viral antigens for cytotoxic T cell priming.

Authors:  Stefan Freigang; Denise Egger; Kurt Bienz; Hans Hengartner; Rolf M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

3.  Anti H-2Dd alloreactivity mediated by herpes-simplex-virus specific cytotoxic H-2k T lymphocytes is associated with H-2Dk.

Authors:  K Pfizenmaier; H Jung; R Kurrle; M Röllinghoff; H Wagner
Journal:  Immunogenetics       Date:  1980       Impact factor: 2.846

4.  Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides.

Authors:  T Hanke; F L Graham; K L Rosenthal; D C Johnson
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

5.  Herpes simplex virus glycoproteins: isolation of mutants resistant to immune cytolysis.

Authors:  N A Machtiger; B A Pancake; R Eberle; R J Courtney; S S Tevethia; P A Schaffer
Journal:  J Virol       Date:  1980-05       Impact factor: 5.103

6.  Rotavirus-specific protein synthesis is not necessary for recognition of infected cells by virus-specific cytotoxic T lymphocytes.

Authors:  P A Offit; H B Greenberg; K I Dudzik
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

7.  Protection of mice from herpes simplex virus-induced retinitis by in vitro-activated immune cells.

Authors:  J U Igietseme; P J Calzada; A R Gonzalez; J W Streilein; S S Atherton
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

8.  Mechanisms of protection against herpes simplex virus type 1-induced retinal necrosis by in vitro-activated T lymphocytes.

Authors:  J U Igietseme; J W Streilein; F Miranda; S J Feinerman; S S Atherton
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

9.  Characterization of the cytolytic T-lymphocyte response to a candidate vaccine strain of equine herpesvirus 1 in CBA mice.

Authors:  P M Smith; Y Zhang; S R Jennings; D J O'Callaghan
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Mapping of a herpes simplex virus type 2-encoded function that affects the susceptibility of herpes simplex virus-infected target cells to lysis by herpes simplex virus-specific cytotoxic T lymphocytes.

Authors:  V C Carter; S R Jennings; P L Rice; S S Tevethia
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.